Salarius Pharmaceuticals, Inc. - SLRX Operating profit EBITDA
EBITDA volatility illustrates the current capital restructuring of Salarius Pharmaceuticals (SLRX) and the priority placed on mid-stage trials. The value 0.00 expresses the current value of the metric. The business relies on a virtual manufacturing model utilizing third-party contractors in the US. Profit potential is driven by multi-year patents in epigenetic therapy aimed at developing targeted anti-tumor drugs.
Salarius Pharmaceuticals, Inc. (SLRX) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Salarius Pharmaceuticals|SLRX - Long-Term Debt to Capital|Short-Term Debt to Capital Salarius Pharmaceuticals Inc|SLRX - Company Debts|Debt to Book Capitalization Ratio Salarius Pharmaceuticals|SLRX - Company Long-Term Debts|Company Short-Term Debts Salarius Pharmaceuticals|Intermediate Coverage Ratio salariuspharma.com
- earnings and market ratios statistics:
SLRX - Net Profit|Company Profit Forecast Salarius Pharmaceuticals|SLRX - Price to Earnings Ratio|Forward P/E Multiple salariuspharma.com|SLRX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Salarius Pharmaceuticals|SLRX - Operating profit before deduction of amortization|Earnings per share for the trailing year Salarius Pharmaceuticals|SLRX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months salariuspharma.com|SLRX - Earnings growth in current year|Expected earnings per share trend next year Salarius Pharmaceuticals
Analysis of all company metrics:Salarius Pharma (SLRX)
Conservative capital requires a transparent assessment of operational efficiency to minimize drawdown risks. This indicator measures real cash flow from core operations before deducting depreciation and the cost of borrowed capital, which is critical under tight monetary policy. Given the non-cyclical nature of targeted oncology therapy and the independence of research and development from GDP, the calculated EBITDA of Salarius Pharmaceuticals (SLRX) demonstrates the resilience of the company's fundamental metrics to macroeconomic shocks.
Who Salarius Pharmaceuticals competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|Operating income before deduction of amortization erasca.com|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|AURA - Profit before payment of interest, taxes and amortization|CADL: Profit before payment of interest, taxes and amortization|ARAY: Operating profit EBITDA|SELLAS Life Sciences Group (SLS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Actuate Therapeutics|CTOR: Income before deduction of interest, taxes and amortization|Operating profit EBITDA HURA|Operating income before deduction of amortization Protara Tx|Fate Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Aadi Bioscience, Inc. WHWK|TCRX - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Champions Oncology CSBR|XBIT (xbiotech.com) - Operating profit before deduction of amortization|CEL-SCI - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization OS Therapies Incorporated|radiopharmtheranostics.com - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA ARTV|ANL (adlainortye.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA VERU (Veru Pharma)|Operating profit EBITDA Tempest Therapeutics Corp TPST|XLO - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RENB (Renovaro Inc.)|muraloncology.com (MURA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Kairos Pharma|OKUR (OnKure Therapeutics, Inc.) - Operating profit EBITDA|Operating profit EBITDA CytoMed|Operating profit EBITDA CRIS|Operating profit before deduction of amortization apollomicsinc.com APLM|Operating profit EBITDA THAR (Tharimmune)|Advanced Biomed Inc. (ADVB) - Profit before interest, taxes and amortization|GNPX: Operating profit before deduction of amortization|CLDI - Operating profit EBITDA|SBFM (Sunshine Biopharma, Inc.) - Operating profit before deduction of amortization|XBIO: Company profit before taxes, interest and amortization|PPBT (Purple Biotech Ltd.) - Operating profit EBITDA|AON (AONC) - Operating income before deduction of amortization|Operating profit EBITDA BGNE|Operating profit before deduction of amortization Checkpoint Therapeutics Inc CKPT|Operating profit EBITDA ELEV (Elevation Oncology)|Operating profit EBITDA iCAD Inc. ICAD|IKNA - Profit before payment of interest, taxes and amortization|NTBL: Profit before payment of interest, taxes and amortization|viracta.com (VIRX) - Profit before payment of interest, taxes and amortization|MOR - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization NAYA Biosciences|ascentage.com (AAPGV) - Operating income before deduction of amortization
